Lantern Pharma

LTRNPhase 3

Founded 2007lanternpharma.com

Lantern Pharma is an emerging, oncology-focused biopharmaceutical company at the intersection of artificial intelligence, genomics, and machine learning. Its core asset is the RADR® platform, which leverages approximately 200 billion oncology-focused data points and over 200 ML algorithms to de-risk and accelerate drug development. The company's mission is to deliver targeted therapies to the right cancer patients, with a current portfolio spanning three lead drug candidates and an ADC program across 12 cancer indications.

Market Cap

$23.8M

Founded

2007

Focus

AI / Machine LearningSmall Molecules

LTRN · Stock Price

USD 2.135.01 (-70.17%)

Historical price data

AI Company Overview

Technology Platform

RADR® is a proprietary AI and machine learning platform that leverages ~200 billion oncology-focused data points and over 200 ML algorithms to accelerate drug discovery, identify biomarkers, and de-risk clinical trials in oncology.

Pipeline Snapshot

7 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitax...	Non-small Cell Lung Cancer	Phase 3
BNP7787 + Placebo	Breast Neoplasms	Phase 3
LP-300 + Pemetrexed + Carboplatin	Adenocarcinoma of Lung	Phase 2
Irofulven	Metastatic Castration-Resistant Prostate Cancer Patients	Phase 2
STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on ...	Histopathology Confirmed Supratentorial GBM at First Recurrence	Phase 1/2

Opportunities

The primary growth opportunity lies in validating its RADR® AI platform through clinical success, which could enable rapid pipeline expansion, lucrative pharma partnerships, and the establishment of a new, more efficient drug development model.

The $200B+ oncology market and the higher success rates of biomarker-driven trials provide a massive addressable market.

Risk Factors

Key risks include clinical trial failure of its lead assets, inability of the AI platform to deliver on its promise of de-risking development, the need for substantial dilutive financing to fund operations, and intense competition from both AI drug discovery firms and traditional oncology biopharma companies.

Competitive Landscape

Lantern Pharma competes with AI-driven drug discovery platforms (e.g., Recursion, Exscientia) and will face therapeutic competition for each pipeline candidate. Its differentiation is its fully integrated 'Platform + Pipeline' model focused exclusively on oncology, aiming to use AI not just for discovery but to directly increase clinical trial success rates.